Brief: Orchard Therapeutics Announces First Patient Dosed With Otl-201 Gene Therapy In Proof-Of-Concept Clinical Trial For Sanfilippo Syndrome
27/04/2020 12:04
April 27 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH
OTL-201
GENE THERAPY IN PROOF-OF-CONCEPT CLINICAL TRIAL FOR SANFILIPPO
SYNDROME (MPS-IIIA)
Source text for Eikon: ID:nGNXb8tg6f
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln